|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||0.3700 - 0.4250|
|52 Week Range||0.2210 - 1.7400|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
We are witnessing a new age of medicine with the increasing acceptance of people’s right to what goes inside their bodies. Over the past decade, several researches have come out supporting psychedelic-inspired medicines in treating conditions including addiction, depression, and ADHD. Hence, the “shroom boom” is here and is likely to propel psychedelic stocks as an attractive investment option. The increasing prevalence of depression, anxiety, and other related mental conditions are fueling the industry’s growth. According to Data Bridge Market Research, the industry is set to grow with a compound annual growth rate of 16.3% over the next eight years. Major players in Big Pharma are making big moves in the sector, and with greater regulatory assent, things will move quickly. Hence, there are massive investment opportunities for investors who can narrow out the companies with the most potential.InvestorPlace - Stock Market News, Stock Advice & Trading Tips 7 Innovative Stocks Pushing Our World Ahead Three of the most promising psychedelic stocks include: Mind Medicine (OTCMKTS: MMEDF) Revive Therapeutics (OTCMKTS: RVVTF) Champignon Brands (OTCMKTS: SHRMF) Psychedelic Stocks to Buy: Mind Medicine (MMEDF) Source: Lightspring / Shutterstock.com Mind Medicine is New York City-based neuro-pharmaceutical company that is involved in the research, development, and deployment of psychedelic-inspired medicines. With a market capitalization of over $180 million, it is the first psychedelics company to go public. Moreover, the NEO stock exchange granted final approval for its listing this year, which is a monumental breakthrough for the industry. The company has an array of projects in its pipeline at different stages of production. It is working with psychedelic drugs such as LSD, DMT, 18-MC, and MDMA as a potential treatment for various mental ailments. Moreover, it has recently acquired licenses for nine of its trials on MDMA from the Liechti Lab in Switzerland. Additionally, Mind Medicine has recently launched a human safety study in finding a possible solution to the opioid crisis. With a healthy cash balance of $24 million, the company will continue to innovate pushing MMEDF stock higher up its peers, making it one of the best psychedelic stocks to buy. Revive Therapeutics (RVVTF) Source: Maksim Shmeljov / Shutterstock.com Revive Therapeutics is a Canadian life sciences company that specializes in the research and development of therapeutics for rare disorders and infections. The stock is up 511% this year on the back of several interesting developments with its Covid-19 drug. The company is working on repurposing its rheumatoid arthritis drug for treating mild cases of Covid-19. However, the company’s future prospects lie with its psychedelics business which is the primary growth catalyst for RVVTF stock Revive recently completed the acquisition of Psilocin Pharma Corp, a company that specializes in the development of psilocybin-based therapeutics. Psilocybin is essentially a hallucinogen that activates serotonin receptors which affect mood, perception and cognition. 7 Innovative Stocks Pushing Our World Ahead The company is investing heavily in psilocybin and is investigating different oral dosage forms of the drug. Additionally, it has inked a deal with the Board of Regents of the University of Wisconsin to study psilocybin as a treatment for methamphetamine addicts. Champignon Brands (SHMRF) Source: Matej Kastelic / Shutterstock Champignon Brands is a human optimization sciences company that specializes in the development and commercialization of ketamine and psychedelic medicine. It is one of the first companies in the industry to go public completing its $2.85 million IPO this year. The company is currently involved in expanding its product portfolio through extensive clinical trials and its network of ketamine clinics. The company recently appointed Dr. Roger McIntyre as its new CEO. McIntyre is an experienced professional in the industry having served as the head of the mood disorders unit at Toronto’s University Health Network. Under his command, the goal is for Champignon to become the world leader in the development of ketamine solutions. Additionally, this year the company raised $10 million through private placement and a California-based ketamine treatment center. Hence, the company aims to capture a sizeable share of the North American region and maximize stockholder returns from SHMRF stock. On Penny Stocks and Low-Volume Stocks: With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That’s because these “penny stocks” are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that InvestorPlace.com’s writers disclose this fact and warn readers of the risks. Read More: Penny Stocks – How to Profit Without Getting Scammed. On the date of publication, Muslim Farooque did not have (either directly or indirectly) any positions in the securities mentioned in this article. More From InvestorPlace Why Everyone Is Investing in 5G All WRONG America’s #1 Stock Picker Reveals His Next 1,000% Winner Revolutionary Tech Behind 5G Rollout Is Being Pioneered By This 1 Company Could Tiny “Super” Battery Kill Big Tech? The post 3 Psychedelic Stocks Gaining More Acceptance appeared first on InvestorPlace.
VANCOUVER, BC, Oct. 5, 2020 /CNW/ - Dr.
VANCOUVER, British Columbia, Sept. 15, 2020 (GLOBE NEWSWIRE) -- Champignon Brands Inc. (CSE: SHRM) (the “Company”) continues to work with the British Columbia Securities Commission (the “Commission”) to address an ongoing continuous disclosure review. Since the review was commenced, the Company has arranged for: * Filing of business acquisition reports (collectively, the “Business Acquisition Reports”) in connection with the acquisitions of Artisan Growers Ltd., Novo Formulations Ltd. and Tassili Life Sciences Corp. * Revocation of the initial cease trade order issued by the Commission on June 19, 2020. * Preparation of financial disclosure in connection with the acquisition of AltMed Capital Corp. (“AltMed”). Compilation of the statements is at an advanced stage, and the Company expects this work to be concluded shortly.Continuous Disclosure ReviewOn June 19, 2020, the Company was notified by the Commission that it would be subject to a continuous disclosure review. Such reviews are conducted by the Commission for the purposes of ensuring compliance with the continuous disclosure obligations imposed by applicable Canadian securities laws. In the case of the Company, this review relates to the Company’s disclosure obligations since it became a reporting issuer on February 6, 2020 and includes a review of the disclosure surrounding acquisitions completed by the Company since that time.In connection with the review, on June 19, 2020, the Commission issued a cease trade order suspending trading in the securities of the Company pending the filing of Business Acquisition Reports in connection with the acquisitions of Artisan Growers Ltd., Novo Formulations Ltd. and Tassili Life Sciences Corp. As a result of the cease trade order, trading in the common shares of the Company was suspended on the Canadian Securities Exchange.The Business Acquisition Reports were filed by the Company on July 21, 2020, during which time the Company continued to work with the Commission to address comments received in the course of the disclosure review. As a result of the filing of the Business Acquisition Reports, on August 26, 2020, the Commission revoked the cease trade order previously issued on June 19, 2020. Concurrently with the revocation, the Commission issued a replacement cease trade order (the “Replacement Order”), pending the filing of a revised material change report (the “Material Change Report”) in connection with the acquisition by the Company of AltMed.The Company previously filed a Material Change Report on May 11, 2020, in connection with the acquisition of AltMed. The Replacement Order will remain in effect until a revised Material Change Report is filed which contains the disclosure required for a restructuring transaction in accordance with National Instrument 51-102 – Continuous Disclosure Obligations.Prior to finalization of a revised Material Change Report, the Company is required to finalize the accounting treatment for the acquisition of AltMed. The Company has concluded, in discussions with its external auditor and accounting advisors, that the acquisition of AltMed should be treated as a reverse-takeover in accordance with IFRS 3 – Business Combinations. As a result of this conclusion, AltMed is treated as the acquiror for accounting purposes and the Company is in the process of compiling the financial statements of AltMed for the six-month period ended June 30, 2020 to meet disclosure requirements. Compilation of the statements is at an advanced stage, and the Company expects this work to be concluded shortly.The Company remains committed to working with the Commission to assist in completion of the review and revocation of the Replacement Order in a timely fashion. Compliance with its continuous disclosure obligations remains of paramount importance to the Company, and its board of directors, and the Company will continue to update shareholders as work with the Commission progresses.ON BEHALF OF THE BOARD OF DIRECTORSDr. Roger McIntyre Chief Executive Officer E: email@example.comFOR INVESTOR INQUIRIES:Champignon Brands | Storyboard Communications Investor Relations, Toronto, Canada Investor Line: +1 (833) 375-9995 x611 E: firstname.lastname@example.orgFOR CHAMPIGNON BRANDS FRENCH INQUIRIES:Remy Scalabrini Maricom Inc. E: email@example.com T: (888) 585-MARIThe Canadian Securities Exchange and its Information Service Provider have not reviewed and do not accept responsibility for the accuracy or adequacy of this release.Forward-looking Information Cautionary Statement This news release contains forward-looking statements within the meaning of applicable securities laws. All statements that are not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance are “forward-looking statements.” Forward-looking statements can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, events, or developments to be materially different from any future results, events or developments expressed or implied by such forward looking statements. Such risks and uncertainties include, among others, the Company’s ability to finalize financial disclosure surrounding the acquisition of AltMed and meet the requirements prescribed for the revocation of the Replacement Order. These factors should be considered carefully, and readers are cautioned not to place undue reliance on such forward-looking statements. Although the Company has attempted to identify important risk factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other risk factors that cause actions, events or results to differ from those anticipated, estimated or intended. Additional information identifying risks and uncertainties that could affect financial results is contained in the Company’s filings with Canadian securities regulators, which are available at www.sedar.com. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in forward-looking statements. The Company has no obligation to update any forward-looking statement, even if new information becomes available.